JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 130.49 Billion KRW | 21.49% |
| 2022 | 107.4 Billion KRW | 87.2% |
| 2021 | 57.37 Billion KRW | 263.32% |
| 2020 | 15.79 Billion KRW | -8.45% |
| 2019 | 17.25 Billion KRW | -36.33% |
| 2018 | 27.09 Billion KRW | 120.5% |
| 2017 | 12.28 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 118.04 Billion KRW | 0.34% |
| 2024 Q1 | 116.99 Billion KRW | -10.35% |
| 2023 Q1 | 109.53 Billion KRW | 1.97% |
| 2023 FY | 130.49 Billion KRW | 21.49% |
| 2023 Q4 | 130.49 Billion KRW | 10.78% |
| 2023 Q3 | 117.79 Billion KRW | 5.3% |
| 2023 Q2 | 111.86 Billion KRW | 2.13% |
| 2022 Q4 | 107.4 Billion KRW | -4.43% |
| 2022 Q3 | 112.39 Billion KRW | 1.77% |
| 2022 Q2 | 110.44 Billion KRW | 88.96% |
| 2022 Q1 | 58.44 Billion KRW | 1.86% |
| 2022 FY | 107.4 Billion KRW | 87.2% |
| 2021 Q2 | 14.37 Billion KRW | 11.26% |
| 2021 Q4 | 57.37 Billion KRW | -1.14% |
| 2021 FY | 57.37 Billion KRW | 263.32% |
| 2021 Q1 | 12.91 Billion KRW | 0.0% |
| 2021 Q3 | 58.04 Billion KRW | 303.9% |
| 2020 Q1 | - KRW | 0.0% |
| 2020 FY | 15.79 Billion KRW | -8.45% |
| 2020 Q3 | - KRW | 0.0% |
| 2020 Q4 | - KRW | 0.0% |
| 2020 Q2 | - KRW | 0.0% |
| 2019 Q4 | - KRW | 0.0% |
| 2019 FY | 17.25 Billion KRW | -36.33% |
| 2019 Q3 | - KRW | 0.0% |
| 2019 Q1 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 FY | 27.09 Billion KRW | 120.5% |
| 2017 FY | 12.28 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Co., Ltd. | 62.7 Billion KRW | -108.111% |
| iNtRON Biotechnology, Inc. | 402.9 Million KRW | -32288.689% |
| BINEX Co., Ltd. | 53.5 Billion KRW | -143.887% |
| Bioneer Corporation | 44.63 Billion KRW | -192.333% |
| Anterogen.Co.,Ltd. | 9.74 Billion KRW | -1239.751% |
| MEDIPOST Co., Ltd. | 52.33 Billion KRW | -149.337% |
| CrystalGenomics, Inc. | 32 Billion USD | -307.763% |
| Helixmith Co., Ltd | 20.22 Billion KRW | -545.14% |
| Chabiotech Co.,Ltd. | 449.63 Billion KRW | 70.977% |
| Medy-Tox Inc. | 82.83 Billion KRW | -57.548% |
| Peptron, Inc. | 9.13 Billion KRW | -1328.855% |
| Amicogen, Inc. | 149.59 Billion KRW | 12.766% |
| Genexine, Inc. | 67.42 Billion KRW | -93.538% |
| HLB Therapeutics Co.,Ltd. | 10.02 Billion KRW | -1202.061% |
| LegoChem Biosciences, Inc. | 12.64 Billion KRW | -932.093% |
| ALTEOGEN Inc. | 83.76 Billion KRW | -55.782% |
| PharmaResearch Co., Ltd. | 34.3 Billion KRW | -280.384% |
| SillaJen, Inc. | 9.69 Billion KRW | -1245.8% |
| OliX Pharmaceuticals,Inc | 39.35 Billion KRW | -231.57% |
| Genomictree Inc. | 1.83 Billion KRW | -7012.886% |
| MedPacto, Inc. | 8.6 Billion KRW | -1416.682% |
| D&D Pharmatech | 8.13 Billion KRW | -1504.281% |
| EASY BIO,Inc. | 82.27 Billion KRW | -58.605% |
| GI Innovation, Inc. | 3.72 Billion KRW | -3407.202% |